Corporate / M&A

Capital Markets

IP / IT

Financing

Investment Products

Homburger News

Share-Image Teamplate Deals-and-Cases

On June 18, 2024, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had entered into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group, Asia&#8217;s largest healthcare-focused investment firm. Santhera is monetizing 75% of its future royalty income streams from its North America and Greater China outlicensing of its marketed product AGAMREE®. In addition, Santhera entered into a commitment letter for a CHF 35 m senior secured term loan financing with certain funds managed by Highbridge Capital. The transaction also includes changes to existing financing arrangements with Highbridge Capital as well as tie issuance of warrants to Highbridge Capital.
Homburger advised Santhera on the Swiss law and tax aspects of the transaction. The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A, Capital Markets) and included Eduard De Zordi, Laura Müller and Michelle Wolf (all Financing and Investment Products, Capital Markets), Stefan Oesterhelt (Tax), Gregor Bühler and Joel Fink (IP / IT), Jasmin Künzle (Corporate / M&amp;A, Capital Markets). Ropes &amp; Gray acted as U.S. counsel to Santhera.

Homburger advised Santhera in connection with its up to CHF 69 m Royalty and Debt Financing

Apellis_web_640x140

On May 13, 2024, Apellis Pharmaceuticals completed Apellis group's USD 475 m senior secured credit facilities financing

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

On May 13, 2024, Apellis Pharmaceuticals completed Apellis group&#8217;s USD 475 m senior secured credit facilities financing. Homburger advised Apellis with respect to all Swiss legal aspects of the transaction.
The Apellis group, centered around Apellis Pharmaceuticals, Inc., is a leading biopharmaceutical company specializing in the development and commercialization of therapeutic compounds aimed at treating a range of serious diseases. The group focuses on advancing innovative therapies targeting the complement system and is renowned for its pioneering work in ophthalmology and hematology.
The Homburger team was led by Daniel Haeberli and included Laura Müller, Yulia Shaburnykova (all Financing) and Stefan Oesterhelt (Tax).

ING-webnews

Homburger and ING Bank

Homburger acted as Swiss counsel to ING Bank in its capacity as coordinator, bookrunner and mandated lead arranger, and as documentation agent in connection with the refinancing of Axpo Holding AG&#8217;s existing credit lines through a EUR 7 bn sustainability-linked revolving credit facility with an international syndicate of more than 30 banks. This new sustainability-linked credit facility is for a three-year term, with extension/increase options and is linked to the achievement of targets for the expansion of renewable energies, the proportion of women in management positions, and the number of apprentices employed.
Homburger advised ING Bank and all other syndicate banks with regard to all Swiss legal aspects of the financing transaction.
The Homburger team was led by Jürg Frick and comprised Stefan Bindschedler, Laura Müller and Céline Rüegg (all Financing and Investment Products).

Laura K.
Müller

Homburger advised Santhera in connection with its up to CHF 69 m Royalty and Debt Financing

Homburger advised Apellis Pharmaceuticals, Inc. on its senior secured USD 475 m financing

Homburger advised ING Bank in connection with Axpo Holding AG's new EUR 7 bn Sustainability-Linked Revolving Credit Facility

Anti-Money Laundering 2023: Switzerland

Join the Team

Laura K. Müller

Career

Languages

Bar Registration

Teams